KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Cost of Revenue: 2010-2025

Historic Cost of Revenue for Halozyme Therapeutics (HALO) over the last 16 years, with Sep 2025 value amounting to $55.2 million.

  • Halozyme Therapeutics' Cost of Revenue rose 11.77% to $55.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.1 million, marking a year-over-year increase of 13.20%. This contributed to the annual value of $159.4 million for FY2024, which is 17.13% down from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Cost of Revenue is $55.2 million, which was up 19.16% from $46.4 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Cost of Revenue registered a high of $55.2 million during Q3 2025, and its lowest value of $15.9 million during Q1 2022.
  • Moreover, its 3-year median value for Cost of Revenue was $48.4 million (2025), whereas its average is $45.6 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first spiked by 301.01% in 2021, then declined by 20.90% in 2024.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Cost of Revenue stood at $21.6 million in 2021, then soared by 95.12% to $42.1 million in 2022, then grew by 24.16% to $52.3 million in 2023, then decreased by 19.59% to $42.1 million in 2024, then increased by 11.77% to $55.2 million in 2025.
  • Its Cost of Revenue stands at $55.2 million for Q3 2025, versus $46.4 million for Q2 2025 and $48.4 million for Q1 2025.